Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates and working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Non-animal alternative testing industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Product type trends
2.1.4 Method trends
2.1.5 Technology trends
2.1.6 Application trends
2.1.7 End-use trends
Chapter 3 Non-animal Alternative Testing Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Technological advances in drug development
3.2.1.2 Growing investments and research grants for developing alternative technologies
3.2.1.3 Increasing ban on using animal models for research purposes
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulations related to safety, efficacy and quality
3.3 Growth potential analysis
3.3.1 By product type
3.3.2 By method
3.3.3 By technology
3.3.4 By application
3.3.5 By end-use
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company positioning matrix
4.4 Competitive analysis of major market players
4.5 Strategic outlook matrix
4.6 Strategy dashboard, 2022
Chapter 5 Non-animal Alternative Testing Market, By Product Type (USD Million)
5.1 Key trends, by product type
5.2 Organ-on-chips
5.3 Cell lines
5.4 Tissue lines
Chapter 6 Non-animal Alternative Testing Market, By Method (USD Million)
6.1 Key trends, by method
6.2 Ex vivo testing
6.3 Computer modelling
6.4 Cellular assay
6.5 Biochemical assay
Chapter 7 Non-animal Alternative Testing Market, By Technology (USD Million)
7.1 Key trends, by technology
7.2 Cell culture technology
7.3 High throughput technology
7.4 Molecular imaging
7.5 Omics technology
Chapter 8 Non-animal Alternative Testing Market, By Application (USD Million)
8.1 Key trends, by application
8.2 Infectious diseases
8.3 Immunological diseases
8.4 Oncology
8.5 Cardiovascular diseases
8.6 Diabetes
8.7 Genetic diseases
8.8 Neurological diseases
Chapter 9 Non-animal Alternative Testing Market, By End-use (USD Million)
9.1 Key trends, by end-use
9.2 Pharmaceutical companies
9.3 Biotechnological companies
9.4 Research institutes and academics
9.5 CROs
9.6 Other end-users
Chapter 10 Non-animal alternative testing Market Estimates and Forecast, By Region (USD Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East & Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East & Africa
Chapter 11 Company Profiles
11.1 AlveoliX AG
11.2 MIMETAS
11.3 MatTek Corporation
11.4 Emulate, Inc.
11.5 VITROCELL Systems GmbH
11.6 Bio-Rad Laboratories, Inc.
11.7 Hurel Corporation, Evotec SE
11.8 MB Research Laboratories
11.9 TissUse GmbH
